Paul Monier, MD
Infectious Disease · Thibodaux, LANPI 1669440780
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,650 of the $7,676 with a category attached, or 60.6%. Insmed, Inc. accounts for 96.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,935 and has fallen 99.7% since, to $19 in 2024.
Across 28 payments — averaging $274.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$79
- Romark Laboratories, LC$47
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$34
- Lilly USA, LLC$24
- Ironwood Pharmaceuticals, Inc$19
- plus $34 from 2 others
What the payments were for
- Consulting fees$1,50020%
- Speaking & faculty fees$4,65061%
- Travel & lodging$91512%
- Food & beverage$4746%
- Education$1372%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 14 | $7,438 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| Romark Laboratories, LC | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Lilly USA, LLC | 1 | $24 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$7,190
How this compares
$7,676 in reported general payments places this provider in the 85th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 39 | $32,195 |
| ErtapenemErtapenem Sodium | 44 | $14,173 |
| Vancomycin Hcl | 80 | $11,432 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 25 | $4,522 |
| Cefepime Hcl | 24 | $2,416 |
| Ampicillin Sodium | 11 | $2,250 |
| Doxycycline Hyclate | 75 | $2,019 |
| Linezolid | 23 | $2,008 |
| Cefazolin Sodium | 23 | $1,972 |
| CeftriaxoneCeftriaxone Sodium | 27 | $1,495 |
| Rifampin | 29 | $1,149 |
| Ethambutol Hcl | 33 | $1,058 |
| Clindamycin Hcl | 37 | $744 |
| Cephalexin | 35 | $675 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 28 | $518 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Thibodaux
- Hector Brunet RodriguezShreveport$592K
- Guillermo Padilla-PinedaShreveport$106K
- Eric EhrensingNew Orleans$97K
- Meredith ClementNew Orleans$93K
- Rebecca LillisNew Orleans$60K
- Stephanie TaylorNew Orleans$25K
- Edwin SwiatloNew Orleans$22K
- John DepaulaMetairie$17K
- Frank RabitoMetairie$13K
- Jihad El-HayekShreveport$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.